<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-058426</identifier>
<setSpec>1137-6821</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Beta-blockers in emergencies and in mobile ICUs</dc:title>
<dc:description xml:lang="en">Beta receptor-blocking drugs inhibit the binding of catecholamines to Beta-adrenergic receptors. This action results in the antianginous, antiarrhythmic and antihypertensive properties that explain their leading therapeutic indications in Emergency Medicine: ischaemic heart disease (acute myocardial infarction and unstable angina), supraventricular tachyarrhythmias (for controlling the ventricyular rate) and hypertensive emergencies (where they are indispensable in the management of acute aortic dissection). In the emergency environment, and particularly in the mobile ICUs, thos Beta-blockers are mainly used that are available for parenteral administration: propranolol, labetalol, atenolol, metoprolol and esmolol. The short half-life of esmolol leads to an easier dosing for symptomatic control and renders it particularly safe as compared to other members of this pharmacotherapeutic group, fundamentally in the management of patients in unstable conditions and of those in whom there is a risk of adverse reactions to beta-blockers (AU)</dc:description>
<dc:creator>Laguna del Estal, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los fármacos betabloqueantes la uinhiben nión de las catecolamisnas a los receptores beta adrenérgicos, lo que les confiere propiedades antianginosas, antiarrítmicas y antihipertensivas que explican sus principales indicadiones terapéuticas en Medicina de Urgencias: cardiopatía isquémica (infarto agudo de miocardio y angina inestable), taquiarritmias supraventriculares (para controlar la frecuencia ventricular) y emergencias hipertensivas (resultando indispensables en el tratamiento de la disección aórtica aguda). En urgencias, y especialemente en UVIs móviles, se emplean fundamentalmente los betabloqueantes disponibles para administración parenteral: propranolol, labetalol, atenolol, metoprolol y esmolol. La vida media breve de esmolol facilita su dosificación para control sintomático y lo hace especialmente seguro frente a otros fármacos de su grupo, fundamentalmente en el tratamiento de enfermos inestables y en los que exista la posibilidad de que desarrollen reacciones adversas a los betabloqueantes (AU)</dc:description>
<dc:source>Emergencias (Sant Vicenç dels Horts);12(6): 407-415, dic. 2000. tab</dc:source>
<dc:identifier>ibc-058426</dc:identifier>
<dc:title xml:lang="es">Betabloqueantes en urgencies y UVIs móviles</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30650^s22080</dc:subject>
<dc:subject>^d322^s22073</dc:subject>
<dc:subject>^d9142^s22066</dc:subject>
<dc:subject>^d322^s22000</dc:subject>
<dc:subject>^d9142^s22074</dc:subject>
<dc:subject>^d23962^s22073</dc:subject>
<dc:subject>^d30650^s22067</dc:subject>
<dc:subject>^d4705^s22080</dc:subject>
<dc:subject>^d23962^s22000</dc:subject>
<dc:subject>^d13993^s22012</dc:subject>
<dc:subject>^d13993^s22016</dc:subject>
<dc:subject>^d6917^s22074</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200012</dc:date>
</metadata>
</record>
</ibecs-document>
